73 results about "Cognitive disorder" patented technology

The invention discloses a cognitive disorder nostalgic audio-video intervention therapy method, which comprises the following steps of: building a scene containing nostalgic music art, classical movies and retro original sound, playing matched audio and visual materials to a patient, and guiding the patient to perform structured intervention activities such as puzzle, theme recall or emotion sharing. Therefore, memory is stimulated, cognition is exercised, and emotion expression is promoted; according to the invention, by integrating three layouts of audios of nostalgic music art, classical movies and retro original sounds with matched visual elements, a multi-scene nostalgic sensory environment is constructed, and auditory and visual channels of a patient can be synchronously stimulated; compared with single auditory or visual stimulation, the compound sensory stimulation can more effectively activate a plurality of brain areas related to memory and emotion in the brain, so that long-term memory of deep sleep is more intensively aroused, and the strength and awakening efficiency of reminiscence stimulation are greatly improved.

The invention discloses a hybrid federal learning modeling method and device for a neurocognitive impairment evolution trajectory, and the method comprises the steps that a child node receives an expert global model distributed by a central node, and the expert global model is determined by the central node from an expert global model group according to metadata pre-registered by the child node; taking the expert global model as an initial model, and performing localization training by using the local multi-modal non-invasive physiological signal data to obtain a trained local model; extracting global sharing parameters in the trained local model, and uploading the global sharing parameters to a central node; and for the corresponding expert global model, the central node aggregates global shared parameters uploaded by all the child nodes training the expert global model to obtain an updated corresponding expert global model, issues the updated expert global model to the child nodes, and circulates until a termination condition is met. According to the method, the heterogeneous data of the child nodes are adapted, privacy is protected, and the adaptability and accuracy of trajectory prediction are improved.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognition, emotion, memory and depression states and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by mass: radix scutellariae, rhizoma coptidis, radix puerariae, rhizoma anemarrhenae, bitter gourd, rhizoma zingiberis, stiff silkworm, American ginseng and radix notoginseng. Wherein the radix scutellariae and the rhizoma coptidis are monarch drugs and mainly attack the core pathogenesis; the radix puerariae, the rhizoma anemarrhenae and the pseudo-ginseng serve as ministerial drugs, assist monarch drugs and treat secondary pathogenesis; bitter gourd, rhizoma zingiberis, stiff silkworm and American ginseng are used as adjuvant drugs to regulate drug properties and treat and treat both symptoms and root causes; and radix puerariae and pseudo-ginseng are used as conductant drugs for guiding channels or harmonizing the drugs. The traditional Chinese medicine composition disclosed by the invention can be used for preventing and treating cognitive disorder, mood disorder and depressive state caused by metabolic disorder. The traditional Chinese medicine composition is small in side effect, high in individuation and suitable for being taken for a long time, and has an obvious treatment effect.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for improving sleep disorder and treating mood disorder or cognitive disorder. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 20-30 parts of lycium ruthenicum, 30-40 parts of nitraria fruit, 15-25 parts of gastrodia elata, 13-25 parts of hyperforin perforatum and 2-6 parts of lycopene. The traditional Chinese medicine composition provided by the invention is prepared from lycium ruthenicum, nitraria fruit, gastrodia elata, hyperforin perforatum and lycopene according to a specific ratio, and the composition can effectively relieve anxiety behaviors of chronic stress bound anxiety model mice through ways of resisting oxidation and inflammation, regulating expression of neurotransmitters and the like, prolong sleep time and improve sleep quality. The learning ability and the memory ability of cognitive impairment mice induced by scopolamine are improved, and the neuron density of brain tissues is increased, so that the neuroprotective effect is achieved.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention belongs to the technical field of molecular biology, and relates to an application of transferrin (TF) as an internal reference protein in preparation of a reagent for detecting exosome proteins of neurodegenerative diseases. The TF can maintain a stable expression level in nerve cells, brain tissues, blood plasma and serum-derived exosomes of a subject suffering from neurodegenerative diseases, including Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease, and also including neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease. The TF expression variation coefficient is obviously lower than that of a common exosome marker, and the expression level of TF has stronger correlation with the total protein amount of the exosome and is not influenced by external factors such as cell inflammation stress. The TF as the internal reference protein has more excellent performance, can help to more accurately reflect the total loading amount of the sample, and provides a more stable and reliable standardized tool for the field of exosome research.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and / or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.

The invention relates to a composition comprising at least 50 mg / g of one or more omega-3 fatty acids, at least 10 mg / g of one or more xanthophylls, at least 1 mg / g of one or more sterols and at least 2 μg / g of one or more phycoprostanes, and to the use of said composition in particular as a food supplement for the prevention of the onset of cognitive disorders.

This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and / or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. The present invention discloses and describes panels of markers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of markers associated with neurocognitive disorders. In some aspects, the marker panel comprises phosphoglucomutase 1 and / or thymosin beta-4, or an isoform, a variant or a fragment of either protein, alone or in combination with additional markers.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The present disclosure relates generally to medical imaging and, more particularly, it relates to methods and systems for performing processing of magnetic resonance (MR) imaging of the brain which may be useful in the diagnosis of cognitive disorders. More specifically, the invention includes methods for processing cortical diffusion data from a region of a subject's brain, comprising determining values for the Axial Columnar Refraction (ACR) using values for AngleR and Axial Diffusivity.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and / or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.

Disclosed in the present invention are aza-fused ring compounds, and a pharmaceutical composition and the use thereof. The structure of the compounds is shown as formula I. The compounds can effectively inhibit ASM activity, wherein under a micromolar concentration level, the enzyme inhibition rate reaches 100% optimally and the enzyme inhibition IC50 value thereof is lower than 5 nM optimally. The compounds can exert pharmaceutical effects at all of the molecular level, the cell level and the animal level, and exhibit excellent therapeutic effects, and have application prospects in treating ASM-related diseases, e.g. depression, senile dementia, cognitive disorders, stroke, myocardial ischemia, pulmonary fibrosis, chronic obstructive pulmonary diseases, pulmonary injury, pulmonary arterial hypertension, respiratory distress syndrome, cystic fibrosis, fatty liver, liver fibrosis, autoimmune diseases, tumors and diabetes.

The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.

A use of a glucokinase activator or a prodrug thereof, or a pharmaceutically acceptable salt, an isotopic label, a crystal form, a hydrate, a solvate, a diastereomer or an enantiomer in preventing, alleviating or treating cognitive disorders or neurodegenerative diseases in subjects, or delaying the progress of cognitive disorders or neurodegenerative diseases in subjects, or reducing the risk of cognitive disorders or neurodegenerative diseases in subjects.

The present application relates to the fields of medicine, health care products and food technology, and in particular to a traditional Chinese medicine composition for mood and cognitive impairment caused by degenerative diseases, which is made of the following raw materials by weight: 1-35 parts of radix puerariae, 1-35 parts of semen ziziphi spinosae, 1-35 parts of radix bupleuri, 1-35 parts of clematis, 1-35 parts of radix astragali, and 1-35 parts of herba eriodes. The present application has the effects of preventing and treating mood and cognitive impairment caused by various degenerative diseases, reducing anxiety-like response and depression level caused by degenerative diseases, preventing overexcitability of the nervous system, significantly improving learning and cognitive ability, and having stable effects without inhibiting normal nerve activity and hormone level.

The application relates to a voice recognition method and device for screening cognitive dysfunction, wherein the method comprises the following steps: acquiring an audio signal to be detected; inputting the audio signal into a voice recognition model for recognition to obtain a recognition result, wherein an acoustic model part in the voice recognition model is obtained by training voice data; a language model part comprises a general language model and a special disease language model, the special disease language model is obtained according to corresponding text data collected according to Alzheimer's disease and related cognitive dysfunction, the general language model and the special disease language model are self-learning and fused; a feature extraction part is used for acquiring audio features in the audio signal based on the acoustic model part; and a decoder part is used for recognizing the extracted audio features, and in the recognition, the general language model and the special disease language model are selected dynamically according to decoding parameters. The application can balance the recognition effects of general and medical special disease scenes.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.